Contents

Preface ........................................................................................................................................................................xvii
Contributing Authors .............................................................................................................................................xviii

Section I. Toxicology Testing in the Hospital Setting
Barbarajean Magnani, Editor

Chapter 1. Introduction and Organizational Aspects of a Hospital Toxicology Laboratory ......................... 3
Tai C. Kwong and Barbarajean Magnani
Introduction, 3
Emergency Toxicology, 3
Toxicology Testing Supporting Other Clinical Services, 3
On-Site Testing, 4
Confirmation Testing and Adulterant Testing, 4
   Confirmation Testing, 4
   Urine Adulterant Testing, 5
Medical-Legal Testing, 5
   Clinical Testing with Legal Implications, 5
   Legal Testing, 5
Summary, 6

Chapter 2. Supporting the Emergency Department ......................................................................................... 7
Barbarajean Magnani and Tai C. Kwong
Introduction, 7
Tier 1 Tests, 7
   Quantitative Serum Tests, 8
   Urine Qualitative Tests, 9
Tier 2 Tests, 9
Unique Challenges Associated with Testing in the ED, 10
Toxidromes, 12

Chapter 3. Supporting the Pain Service ............................................................................................................ 15
Catherine A. Hammert-Stabler and Barbarajean Magnani
Introduction, 15
Role of the Clinical Laboratory in Pain Management, 16
Samples, Analytes, and Methods, 17
Clinical Pathology Consultations, 21
Alternate Specimens and Issues, 24
Summary and Conclusions, 24
CHAPTER 4. Biomonitoring of Medical Professional Substance Abuse: Practical and Analytical Issues........27
Robert A. Middleberg
Introduction, 27
Treatment and Monitoring of Impaired Medical Professionals, 27
Oversight, 27
Treatment Monitoring, 28
Substances Commonly Abused by Medical Professionals, 28
Analytical Considerations of Medical Professional Testing, 28
General, 28
Preanalytical Considerations, 29
Analyses, 30
Scope of Testing, 30
Screening, 30
Confirmation Testing, 31
Interpretive Issues, 31
Summary, 32

CHAPTER 5. Workplace Drug Testing and the Role of the Medical Review Officer.................................................33
Michael G. Bissell
Introduction, 33
Workplace Drug Testing, 33
The Medical Review Officer, 34
Positivity Criteria and Sources of Legitimate Medical Explanations for HHS 5 Urine Tests, 35
Amphetamines, 35
Amphetamine, 35
Methamphetamine, 35
Cocaine, 36
Marijuana, 36
Opiates, 36
Heroin, 37
Morphine, 37
Codeine, 37
Opiate Identification, 37
Phencyclidine, 37
Medical Review Officer Review of Specimen Validity Testing, 38
Definitions of Specimen Validity Testing Results and Associated Medical Review Officer Actions, 38
Negative or Positive Specimen, 38
Negative Dilute Specimen, 38
Positive Dilute Specimen, 38
Substituted Specimen, 38
Adulterated Specimen, 38
Invalid Drug Test, 39
Summary, 39

CHAPTER 6. The Hospital Autopsy and Toxicology Testing.........................................................................................41
D. Kimberley Molina and Barbarajean Magnani
Introduction, 41
The Autopsy, 41
Specimen Collection, 42
Specimen Selection, 44
Ordering Toxicology Testing, 44
Interpretation of Toxicology Results, 45
Medicolegal Issues, 46
Summary, 47
CHAPTER 7. Regulatory Issues of Toxicology Laboratory Operations ................................................................. 49
Wayne R. Markus
Introduction, 49
CLIA Certification, 49
   CLIA Certificates, 49
   CLIA-Exempt Laboratories, 50
State Exemption from CLIA, 50
Forensic Testing Accreditation, 50
   The CAP FDT Accreditation Program, 50
   Forensic Testing in the Clinical Laboratory, 51
Medical Testing with Legal Implications, 51
Waived Tests, 51
Nonprofit Agencies with Deemed Status to Accredit Laboratories, 51
Five Condition Level Requirements for Accreditation, 52
   First Condition Level Requirement: Proficiency Testing, 52
   Second Condition Level Requirement: Facility Administration, 52
   Third Condition Level Requirement: Quality Systems, 53
      Quality Assurance (Assessment)/Quality Management, 53
      Proficiency Testing and Alternative Performance Assessment, 54
      Evaluation of Proficiency Testing and Alternative Performance Assessment, 54
      Method Validation, 54
   Fourth Condition Level Requirement: Personnel, 56
      Competency Evaluation of Technical Staff, 57
   Fifth Condition Level Requirement: Inspection, 57
ISO 15189, 57
Alcohol and Volatiles Proficiency Testing, 57
Immunossay Urine Drug Screen Proficiency Testing, 57
Broad-Spectrum Urine Drug Screen Proficiency Testing, 58
Whole Blood, Serum, and Plasma Drug Screen Proficiency Testing, 59
Urine Adulteration Proficiency Testing, 59
Summary, 59

CHAPTER 8. Adverse Drug Events, Poisonings, and Abuse .................................................................................. 61
Daniel J. Cobaugh
Introduction, 61
Experience Across the Continuum of Care, 62
Identifying the Point of Occurrence of Adverse Drug Events, 64
Medications Frequently Implicated in Adverse Drug Events, 64
System Failures Versus “Bad Apples,” 65
Poisonings, 66
Drug Abuse and Misuse, 66
Conclusions, 67

Section II. Methodologies for the Toxicology Laboratory
Tai C. Kwong, Editor

CHAPTER 9. Alternate Specimens for Drugs-of-Abuse Testing:
Preanalytical and Interpretative Considerations .................................................................................................. 71
Uttam Garg and Angela M. Ferguson
Introduction, 71
Hair, 71
   Preanalytical and Interpretive Considerations in Drug Testing of Hair Samples, 73
      Environmental or External Contamination, 73
      Hair Color and Drug Incorporation, 74
      Adulteration Issues, 75
CHAPTER 12. Cannabis .........................................................................................................................104
Michael G. Bissell

Descriptive Chemistry, 104
\(\Delta^2\)-tetrahydrocannabinol, 104
\(\Delta^2\)-tetrahydrocannabinolic acid, 105
Cannabinol, 104
Cannabidiol, 105
Origin, 105
Pharmacology, 105
Type of Agent, 105
Context of Human Use, 105
Abuse Potential and Characteristics, 106
Overdose and Toxicity, 106
Adverse Effects and Complications, 107
Central Nervous System, 107
Cardiovascular, 107
Respiratory, 107
Reproductive, 107
Toxic Dose, 108
Pharmacokinetics, Metabolism, and Excretion, 108
Pharmacokinetics, 108
Metabolism, 108
Excretion, 109
Volume of Distribution, 109
Half-Life, 109
Analysis, 109
Analytical Parameters, 109
Specimen Types, Requirements, and Characteristics, 109
Modes of Analysis, 110
Known Analytical Issues and Problems, 110
Clinical Issues, 110
Clinical Interpretation of Analytical Findings, 110
Treatment and Rehabilitation for Overdose and Toxicity, 110

CHAPTER 13. Cocaine .........................................................................................................................112
Michael G. Bissell

Descriptive Chemistry, 112
Cocaine, 112
Cocaine Hydrochloride, 112
Origin, 112
Pharmacology, 112
Type of Agent, 112
Context of Human Use, 112
Intoxication and Abuse, 113
Overdose and Toxicity, 114
Adverse Effects and Complications, 114
  Central Nervous System, 114
  Cardiovascular, 114
  Respiratory, 115
  Musculoskeletal and Renal, 115
  Sexual, 115
  Pregnancy, 115
  Breast-feeding, 115
Toxic Dose, 115
Pharmacokinetics, Metabolism, and Excretion, 116
  Pharmacokinetics, 116
  Metabolism, 116
  Excretion, 117
Analysis, 117
  Analytical Parameters, 117
  Specimen Types, Requirements, and Characteristics, 117
  Modes of Analysis, 117
  Known Analytical Issues and Problems, 117
Clinical Issues, 118
  Clinical Interpretation of Analytical Findings, 118
  Treatment of Acute Overdose, 118

CHAPTER 14. Amphetamines .............................................................................................................. 119
Marion L. Snyder and Stacy Eugenie Melanson
Descriptive Chemistry, 119
  Amphetamine, 119
  Methamphetamine, 119
Origin, 119
Pharmacology, 120
  Type of Agent, 120
  Context of Human Use, 120
  Abuse Potential and Characteristics, 120
  Overdose and Toxicity, 120
  Complications, 120
  Toxic Dose, 120
  Pharmacokinetics, Metabolism, and Excretion, 120
  Pharmacokinetics, 120
  Metabolism and Excretion, 121
Analysis, 121
Clinical Issues, 123
  Clinical Interpretation of Analytical Findings, 123
  Treatment of Overdose and Toxicity, 124

CHAPTER 15. Barbiturates ....................................................................................................................... 126
Marion L. Snyder and Stacy Eugenie Melanson
Descriptive Chemistry, 126
  Amobarbital, 126
  Butalbital, 126
  Butabarbital, 126
  Mephobarbital, 127
  Pentobarbital, 127
  Phenobarbital, 127
  Secobarbital, 127
  Thiopental, 127
Chapter 16. Benzodiazepines

Descriptive Chemistry, 132
- Alprazolam, 132
- Diazepam, 132
- Nordiazepam, 132
- Lorazepam, 133
- Oxazepam, 133
- Chlordiazepoxide, 133
- Triazolam, 133
- Flurazepam, 133
- Flunitrazepam, 134
- Clonazepam, 134

Origin, 134
Pharmacology, 134
- Type of Agent, 134
- Context of Human Use, 134
- Abuse Potential and Characteristics, 134
- Overdose and Toxicity, 135
- Toxic Dose, 135
- Pharmacokinetics, Metabolism, and Excretion, 135
  - Pharmacokinetics, 135
  - Metabolism and Excretion, 135

Analysis, 135
Clinical Issues, 138
  - Clinical Interpretation of Analytical Findings, 138
  - Treatment of Overdose and Toxicity, 138

Chapter 17. Opioids 1: Opiates

Descriptive Chemistry, 140
- Morphine, 140
- Codeine, 140
- Thebaine, 141
- Heroin, 141
- Hydromorphone, 141
- Hydrocodone, 141
- Oxymorphone, 141
- Oxycodone, 142

Origin, 142
Pharmacology, 142
  Type of Agent, 142
  Context of Human Use, 143
  Abuse Potential and Characteristics, 143
  Overdose and Toxicity, 143
  Adverse Effects and Complications, 144
    Cardiovascular, 144
    Respiratory, 144
    Renal, 144
    Metabolic, 144
    Immune, 144
    Reproductive, 144
  Toxic Dose, 144
  Pharmacokinetics, Metabolism, and Excretion, 144
    Pharmacokinetics, 144
    Metabolism, 145
    Excretion, 145
Analysis, 146
  Specimen Types, Requirements, and Characteristics, 146
  Modes of Analysis, 146
  Known Analytical Issues and Problems, 147
Clinical Issues, 147
  Clinical Interpretation of Analytical Findings, 147
  Treatment and Rehabilitation, 147

Chapter 18. Opioids 2: Synthetic Opioids ................................................................. 149
Hoi-Ying Elsie Yu
Descriptive Chemistry, 149
  Fentanyl, 149
  Meperidine, 149
  Propoxyphene, 149
  Tramadol, 150
Origin, 150
Pharmacology, 150
  Type of Agent, 150
  Context of Human Use, 150
  Abuse Potential and Characteristics, 151
  Overdose and Toxicity, 151
  Drug and Disease Interactions, 152
  Toxic Dose, 152
  Pharmacokinetics, Metabolism, and Excretion, 152
    Pharmacokinetics, 152
    Metabolism and Excretion, 153
Analysis, 153
  Specimen Types, Requirements, and Characteristics, 153
  Modes of Analysis, 153
  Known Analytical Issues and Problems, 154
Clinical Issues, 154
  Clinical Interpretation of Analytical Findings, 154
  Treatment and Rehabilitation, 154

Chapter 19. Opioids 3: Synthetic Opioids Continued (Methadone and Buprenorphine) .......... 157
Glynnis B. Ingall and Bharathi Vennapusa
Descriptive Chemistry, 157
  Methadone, 157
  Buprenorphine, 157
Origin, 157
Analysis, 172
   Specimen Types, Requirements, and Characteristics, 172
   Modes of Analysis, 172
Clinical Issues, 173
   Clinical Interpretation of Analytical Findings, 173
   Treatment and Rehabilitation, 173

Section III B. The Toxicology Laboratory’s Test Menu: Toxic Substances and Overdoses
Michael G. Bissell, Editor

Chapter 22. Over-the-Counter Analgesics ................................................................. 179
Hoi-Ying Elsie Yu and Barbarajean Magnani

Introduction, 179
Descriptive Chemistry, 179
   Salicylate, 179
   Acetaminophen, 179
Origin, 179
   Salicylate, 179
   Acetaminophen, 179
Pharmacology, 180
   Type of Agent, 180
   Context of Human Use, 180
   Overdose and Toxicity, 180
      Salicylate, 180
      Acetaminophen, 181
Pharmacokinetics, Metabolism, and Excretion, 182
   Pharmacokinetics, 182
   Metabolism and Excretion, 182
Analysis, 183
   Specimen Types, Requirements, and Characteristics, 183
   Modes of Analysis, 183
      Salicylate, 183
      Acetaminophen, 183
   Known Analytical Issues and Problems, 184
      Salicylate, 184
      Acetaminophen, 184
Clinical Issues, 184
   Clinical Interpretation of Analytical Findings, 184
      Salicylate, 184
      Acetaminophen, 184
   Treatment and Rehabilitation, 185
      Salicylate, 185
      Acetaminophen, 185
   General Considerations for Patients with Potential Analgesic Toxicity, 185

Chapter 23. Non-Ethanol Volatiles and Ethylene Glycol ........................................ 188
Michael G. Bissell

Descriptive Chemistry, 188
   Acetone, 188
   Methanol, 188
   Isopropanol, 188
   Ethylene Glycol, 188
Pharmacology, 188
   Context of Human Use, 189
   Exposure, 189
      Airborne and Workplace Exposure: Hazardous Material (Hazmat) Considerations, 189
      Exposure by Ingestion: Epidemiology, 189
Pharmacokinetics, Metabolism, and Excretion, 190
  Pharmacokinetics, 190
  Metabolism and Excretion, 190
Toxicity, 191
  Acetone, 191
  Methanol, 191
  Isopropanol, 192
  Ethylene Glycol, 192
Analysis, 192
  Specimen Types, Requirements, and Characteristics, 192
  Modes of Analysis, 192
  Known Analytical Issues and Problems, 193
Clinical Issues, 193
  Clinical Interpretation of Analytical Findings, 193
    Acetone and Isopropanol, 193
    Methanol and Ethylene Glycol, 193
  Treatment and Management, 194
    Acetone, 194
    Isopropanol, 194
    Methanol, 194
    Ethylene Glycol, 195

CHAPTER 24. Lead and Other Toxic Metals

Robert A. Middleberg

Introduction, 196
Descriptive Chemistry, 196
  Lead, 196
  Arsenic, 196
  Cadmium, 196
  Mercury, 196
  Thallium, 196
Pharmacology, 196
  History and Context of Human Use, 196
    Lead, 196
    Arsenic, 197
    Cadmium, 197
    Mercury, 197
    Thallium, 197
Exposure, 197
  Lead, 197
  Arsenic, 198
  Cadmium, 198
  Mercury, 198
  Thallium, 198
Toxicokinetics, Metabolism, and Excretion, 199
  Lead, 199
  Arsenic, 199
  Cadmium, 199
  Mercury, 200
  Thallium, 200
Toxicity, 200
  Lead, 200
  Arsenic, 202
  Cadmium, 202
  Mercury, 203
  Thallium, 203
Analysis, 203
Specimen Types, Requirements, and Characteristics, 203
  Lead, 203
  Arsenic, 204
  Cadmium, 204
  Mercury, 204
  Thallium, 204
Modes of Analysis, 204
  Lead, 204
  Arsenic, 204
  Cadmium, 204
  Mercury, 204
  Thallium, 204
Known Analytical Issues and Problems, 204
  Lead, 204
  Cadmium, 204
  Mercury, 204
Clinical Issues, 205
  Clinical Interpretation of Analytical Findings, 205
  Treatment and Management, 205
  Lead, 205
  Arsenic, 205
  Cadmium, 206
  Mercury, 206
  Thallium, 206

Chapter 25. Common Household and Environmental Toxins
(Carbon Monoxide, Cyanide, Organophosphates, Warfarins) ..................................................208

Leland B. Baskin

Introduction, 208
Descriptive Chemistry, 208
  Carbon Monoxide, 208
  Hydrogen Cyanide, 208
  Organophosphates, 208
    Parathion, 208
  Warfarins, 209
    Warfarin, 209
    Dicoumarol, 209
Pharmacology, 209
  History and Context of Human Exposure, 209
    Carbon Monoxide, 209
    Cyanide, 209
    Organophosphates, 209
    Warfarins, 210
Toxicokinetics, Metabolism, and Excretion, 210
  Carbon Monoxide, 210
  Cyanide, 210
  Organophosphates, 210
  Warfarins, 210
Toxicity, 211
  Carbon Monoxide, 211
  Cyanide, 212
  Organophosphates, 212
  Warfarins, 213
Toxic Dose, 213
  Carbon Monoxide, 213
Section IV. Drug Disposition, Toxicokinetics, and Individualization
Alan H.B. Wu, Editor

CHAPTER 26. Pharmacokinetic Concepts for Toxicology and Therapeutic Drug Monitoring ........................................211
Yashpal Agrawal
Introduction, 221
Pharmacokinetics and Pharmacodynamics, 221
Drug Absorption, 221
Bioavailability, 221
First-Pass Metabolism, 222
Drug Distribution, 222
Key Pharmacokinetic Parameters and Concepts, 222
  Volume of Distribution, 222
  Drug Elimination, 223
  Clearance, 223
  Elimination Rate Constant, 224
  Compartmental Models of Pharmacokinetics, 225
    One-Compartment Model, 225
    Two-Compartment Model, 225
  Half-Life, 225
  Concept of Steady State, 226
  Area Under the Curve, 227

CHAPTER 27. Clinical Usefulness of Monitoring Free (Unbound) Concentrations of Therapeutic Drugs .................................................................228
Amitava Dasgupta
Introduction, 228
Candidates for Free Drug Monitoring, 229
Monitoring Concentrations of Free Anticonvulsants, 229
  Rationale for Monitoring Free Phenytoin Concentration, 229
  Rationale for Monitoring Free Valproic Acid Concentration, 231
  Rationale for Monitoring Free Carbamazepine Concentration, 231
When Should Free Anticonvulsant Be Monitored?, 232
  Elevated Free Anticonvulsant Concentrations in Uremia, 232
  Elevated Free Anticonvulsant Levels in Hepatic Disease, 232
  Free Anticonvulsant Concentrations in Patients with AIDS, 233
  Free Anticonvulsants in Pregnancy, 233
  Drug–Drug Interactions and Elevated Free Anticonvulsant Concentrations, 233
Is Free Monitoring Needed for Any New Anticonvulsant?, 234
  Rationale for Free Drug Monitoring of Drugs Bound to Alpha-1-Acid Glycoprotein, 234
  Rationale for Monitoring Free Concentrations of Immunosuppressant Drugs, 235
  Rationale for Monitoring Free Concentrations of Protease Inhibitors, 235
  Monitoring Free Digoxin Concentration, 236
Saliva and Tears: Alternatives to Serum, 236
Assay Techniques for Free Anticonvulsants, 237
Conclusions, 237

Chapter 28. Pharmacogenomic Testing and the Future of Hospital Toxicology .................................................241
Alan H.B. Wu
Introduction, 241
Definitions and Terminology, 241
Reviews and Tools for Pharmacogenomics, 242
Drivers of Clinical Pharmacogenomics, 242
Pharmacogenomic Testing for Therapeutic Efficacy and Toxicity Avoidance, 242
  CYP2C9 and VKORC1 for Warfarin, 242
  CYP2D6 for Tamoxifen, 244
  UGT1A1 for Irinotecan, 244
  CYP2C19 for Clopidogrel, 244
  TPMT for Thiopurine Drugs, 245
  HLA-B Testing to Prevent Delayed Hypersensitivity Reactions, 245
Summary, 246

Section V. Appendices: Templates and FAQs
Tai C. Kwong, Editor
APPENDIX A. Urine Toxic Screen Template .................................................................251
  Barbarajean Magnani

APPENDIX B. Serum Toxic Screen Template ..............................................................255
  Barbarajean Magnani

APPENDIX C. Therapeutic Drug Monitoring Template .................................................261
  Barbarajean Magnani

APPENDIX D. Frequently Asked Questions on Clinical Urine Drugs-of-Abuse Testing .........271
  Tai C. Kwong

Index ..............................................................................................................................276